Source: International Congress 2017 – Notable abstracts in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Albers (Chapel Hill, United States of America). Mepolizumab improves activity limitation in severe eosinophilic asthma. 4673

Member's Comments

No comment yet.

Related content which might interest you: Mepolizumab improves small airway function in severe eosinophilic asthma Source: International Congress 2018 – The value of lung function testing in various pathophysiological conditions Year: 2018 Impact of mepolizumab on work productivity and activity impairment in severe eosinophilic asthma Source: International Congress 2017 – Bronchial asthma management Year: 2017 Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 Improved small airway function by benralizumab in patients with severe eosinophilic asthma Source: Virtual Congress 2020 – From respiratory physiology to clinical practice: exercise and respiratory muscles Year: 2020 Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Effects of formoterol-budesonide combination on residual eosinophilic inflammation in distal airway of patients with well-controlled moderate asthma Source: Annual Congress 2011 - Asthma management and response Year: 2011 Problematic severe asthma Source: Eur Respir Mon 2012; 56: 22-39 Year: 2012 The importance of eosinophilic inflammation in COPD exacerbations Source: International Congress 2017 – COPD management Year: 2017 Anti-IL5 therapy could prevent lung function decline in severe eosinophilic asthma: data from the belgian severe asthma registry Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021 Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Real-life treatment of severe eosinophilic asthma with mepolizumab Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with high and low reversibility Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Factors driving airway eosinophilia in prednisone-dependent severe asthma Source: International Congress 2017 – Pathophysiology and emerging therapies for severe asthma Year: 2017